Age determines response to anti-TNFα treatment in patients with ankylosing spondylitis and is related to TNFα-producing CD8 cells
Open Access
- 15 March 2018
- journal article
- research article
- Published by Springer Nature in Clinical Rheumatology
- Vol. 37 (6) , 1597-1604
Abstract
Younger age is a predictor of good clinical response to treatment with tumour necrosis factor (TNF) α inhibitors in ankylosing spondylitis (AS) patients; therefore, the aim of the study was to determine age-related differences in cellular functions, which can predict the response. High disease activity AS patients were treated with TNFα inhibitors for 12 weeks. Based on the percentage of Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) improvement, patients were divided into responding or non-responding groups. Cytometric and clinical assessment were determined at baseline, 4, and 12 weeks after initiation of anti-TNFα treatment. Expression of activation markers on T cells and intracellular cytokine staining was performed. Baseline percentage of TNFα-producing CD8 cells was lower in responders than in non-responders (20.8 ± 2.9 vs 40.7 ± 8.2; P = 0.04 in T test) and increased in the responding group during the first month of treatment (20.8 ± 2.9 vs 30.3 ± 2.5; P = 0.02). Moreover, its baseline level correlated with age (r = 0.7; P = 0.0009) but not with BASDAI improvement adjusted for age. There were no differences in the baseline percentage of IL-4, IL-17A, and IFNγ within CD4 and CD8 cells nor in the expression of CD25, CD28, and CD69 on these cells between responders and non-responders. However, baseline level of CD4+CD28null cells correlated with the percentage of BASDAI improvement while analysed as a continuous variable adjusted for age (r = − 0.4; P = 0.048). Clinical predictors of response were also determined. Influence of age on the response to anti-TNFα treatment in AS patients could be mediated by TNFα-producing CD8 cells.Keywords
Funding Information
- Uniwersytet Jagielloński Collegium Medicum (K/DSC/003114)
This publication has 27 references indexed in Scilit:
- Body mass does not affect the remission of psoriatic arthritis patients on anti-TNF-α therapyScandinavian Journal of Rheumatology, 2012
- Baseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in ankylosing spondylitis: a prospective longitudinal observational cohort studyArthritis Research & Therapy, 2011
- An Eight-Gene Blood Expression Profile Predicts the Response to Infliximab in Rheumatoid ArthritisPLOS ONE, 2009
- Effectiveness, Safety, and Predictors of Good Clinical Response in 1250 Patients Treated with Adalimumab for Active Ankylosing SpondylitisThe Journal of Rheumatology, 2009
- Preferential type 1 chemokine receptors and cytokine production of CD28− T cells in ankylosing spondylitisAnnals of the Rheumatic Diseases, 2006
- Increased Spontaneous Apoptosis of CD4+CD25+T Cells in Patients with Active Rheumatoid Arthritis Is Reduced by InfliximabAnnals of the New York Academy of Sciences, 2005
- Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor α blockers in ankylosing spondylitisAnnals of the Rheumatic Diseases, 2004
- Inflammatory mediators in the elderlyExperimental Gerontology, 2004
- Aging-related Deficiency of CD28 Expression in CD4+ T Cells Is Associated with the Loss of Gene-specific Nuclear Factor Binding ActivityJournal of Biological Chemistry, 1998
- Evaluation of Diagnostic Criteria for Ankylosing SpondylitisArthritis & Rheumatism, 1984